Viseven

NOVEMBER 9, 2022

Key Opinion Leaders play a critical role in the life sciences industry – pharmaceutical companies often engage them during clinical trials and drug commercialization. It’s about finding HCP leaders with the most influence within the pharmaceutical industry. KOL engagement in pharma.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Communication Drug Development 52

European Pharmaceutical Review

JANUARY 13, 2025

3 Encouragingly, there are many examples of the life sciences sector seeking to embrace sustainable drug development; reconciling the drive for innovation with the need to reduce waste and emissions produced during the R&D process, as well as throughout the product lifecycle.

Packaging 52

Packaging Community Pharmacies Documentation Pharmaceutical Companies 52

PharmaShots

MARCH 6, 2023

Traditionally patients were viewed by pharmaceutical companies as simply users of our products, nowadays they are considered partners working towards a collective goal. As a result of this progression, our industry developed the notion of patient-centricity. AI can even spot malignant tumours invisible to the naked eye.

Drug Development 40

Drug Development Immunization Immunity Pharmaceutical Companies 40

Viseven

DECEMBER 13, 2024

Patient recruitment often required participants to travel to trial sites, like hospitals or research centers, creating barriers due to geographic distance, travel costs, and time away from daily obligations. This restricted participation, limiting accessibility and diversity within trials. However, the pressure to modernize is mounting.

Health and Personal Care Stores 52

Health and Personal Care Stores Communication Documentation Pharmaceutical Companies 52

PharmaShots

FEBRUARY 27, 2023

As a renowned chemist, Dr. Senanayake discussed the need to adopt green chemistry in the process of drug development for cost reduction, timely innovation, and generating less waste than the standard process. According to me the main issue faced during the pandemic was the supply chain of pharmaceuticals.

Biosimilars 40

Biosimilars Diabetes Packaging Hospitals 40

pharmaphorum

MARCH 30, 2021

For example, the company recently launched Rare Answers , a system of innovative and sustainable tools that are designed to help shorten the diagnostic journey for children with a rare disease – developed in collaboration with leading children’s hospitals and technology and data science companies.

Hospitals 111

Hospitals Communication Drug Development Pharmaceutical Companies 111

European Pharmaceutical Review

NOVEMBER 9, 2023

Following her presentation on age-related disease at BioFuture 2023, Executive Vice President of Drug Development for MyMD Pharmaceuticals ® , Jenna Brager, shares with EPR why the company’s next-generation tumour necrosis factor (TNF)-alpha inhibitor has potential in inflammatory and autoimmune disorders.

Drug Development 115

Drug Development Immunity Immunization Pharmaceutical Companies 115

Viseven

MARCH 25, 2025

Thus, if you are a healthcare or pharmaceutical company that still hasn’t implemented any business intelligence tools, now is the best time to consider them. Moreover, healthcare BI allows hospitals to plan their activities better and find out more about how well they perform and what they could change.

Health and Personal Care Stores 52

Health and Personal Care Stores Hospitals Health Insurance Companies Vaccines 52

Pharmaceutical Technology

FEBRUARY 1, 2023

As paediatric hospital wings are flooded with an unprecedented number of respiratory syncytial virus (RSV) cases , healthcare workers have been overwhelmed by an unusually early peak of the RSV season. Pharmaceutical companies are pushing to develop drugs and vaccines for RSV with these populations in mind.

Vaccines 64

Vaccines Drug Development Pharmaceutical Companies Pharmaceutical Companies 64

pharmaphorum

OCTOBER 28, 2020

Data defines modern therapeutics, but this is almost uniquely confined to the clinical trial stages of drug development. Identifying, recruiting, retaining and monitoring patients during this part of the cycle is estimated to cost pharma US$19 billion a year as companies seek to harvest patient experiences.

Vaccines 119

Vaccines Hospitals Pharmaceutical Companies Pharmaceutical Companies 119

Pharmaceutical Technology

MARCH 9, 2023

Innovation S-curve for the pharmaceutical industry Tyrosine kinase inhibitors is a key innovation area in pharmaceutical drug development Tyrosine kinases catalyse the phosphorylation of select tyrosine residues in target proteins by using adenosine triphosphate (ATP). Hoffmann-La Roche and Debiopharm Group.

Hospitals 52

Hospitals Pharmaceutical Companies Pharmaceutical Companies Vaccines 52

pharmaphorum

JANUARY 27, 2023

Late last year, pharmaphorum caught up with Dr Karen Mullen, chief medical officer and VP of clinical & medical affairs at global drug development consultancy Boyds. We talk a lot in clinical trials and drug development about benefit,” Dr Mullen said. But who is benefitting?

Vaccines 111

Vaccines Pharmaceutical Companies Pharmaceutical Companies Documentation 111

pharmaphorum

SEPTEMBER 9, 2021

And that, in turn, can reduce the burden on hospitals and systems, and allow healthcare services to focus their resources even more strategically. Mark Hicken is vice president of strategy for Europe, Middle East and Africa (EMEA) at Janssen, the Pharmaceutical Companies of Johnson & Johnson. About the author.

Communication 52

Communication Pharmaceutical Companies Pharmaceutical Companies Hospitals 52

PharmaShots

FEBRUARY 6, 2023

For clinical trials, the Pulse offers researchers and pharmaceutical companies the ability to capture a full suite of vascular biomarkers necessary to characterize the hemodynamic status of clinical trial participants at their homes and transmit the data directly to the study personnel analyzing the impact of intervention being studied.

Health and Personal Care Stores 53

Health and Personal Care Stores Biosimilars HIPAA Pharmaceutical Companies 53

PharmaShots

APRIL 10, 2023

Moreover, the ceaseless trials of pharmaceutical companies in the research of drugs for several disease conditions have transformed the course of therapeutics. With a pancreas transplant, the condition can be treated permanently How Concerning is Diabetes? According to the WHO, diabetes contributes to 1.5M deaths every year.

Diabetes 40

Diabetes Biosimilars Pharmaceutical Companies Pharmaceutical Companies 40

Viseven

SEPTEMBER 18, 2024

When COVID hit, the urgent need to accelerate drug development meant shrinking timelines from years to months, with no room for compromises on quality. Cloud-based tools allowed pharma companies to capture and share clinical data between research teams both securely and quickly. Why do so many patients leave the clinical trials?

Communication 52

Communication Vaccines Pharmaceutical Companies Pharmaceutical Companies 52

European Pharmaceutical Review

FEBRUARY 20, 2025

China and India together supply more than 70 percent of APIs used in US drug manufacturing, while Europe remains a key supplier of high-value biologics and specialised medicines. 3 Additionally, tariffs could increase lead times for manufacturing, as companies navigate customs barriers and seek alternative suppliers. References 1.

Drug Pricing 20

Drug Pricing Pharmaceutical Manufacturing Generic Medicine Hospitals 20